Cingulate Receives Complete Response Letter from FDA for CTx-1301

Stock Information for Cingulate Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cingulate Inc.

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.